Member Info for researcher1

tom, they have an ADR set up ready for Nasdaq, but I sense they would feel presumptuous doing it before the FDA result - the prospect of those two events in close proximity, which would certainly double the SP from here, is what is driving the US interest. We must remember that the US investors in the Placing at 60p claimed at the time that they were looking for a ten fold gain. With the more recent placing, their expectations will have been lowered to an 8 fold gain = SP circa £4.80.

Fever it is going to spike more tan 30% from these levels if a timely approval comes - IF the SP is already over £1.10 by then, you may be right, but I feel the intraday spike could still be closer to 100% - not least in the realisation the MCAP would still be tiny compared to its potential over the following year or two.

ha ha, where did that decimal point go? wishful thinking...?

I feel 150p will be minimum, irrespective of the price on the day of the announcement, but if it is, say, £1.10, then £2 must be on the cards, falling back to around £160 until additional news comes in...

what thoughts do we have on likely/deserved SP post-FDA? Finncap's 150 p target is for the current state of play (which also balances a strong likelihood of FDA approval). I hope it doesn't surge too high (£2 +) or I may be tempted to top slice, when we all know that is just the start of things.....

we also have to congratulate AN for timing these groundbreaking RNSRs for after the departure of the crass fools at Jupiter.

they could have been more upbeat, but it means the real rerate will happen on March 23, surely worth the wait...

let's forget about him - far more important things to be focussed upon. A golden 3 months coming IMO....

p.s. hope you got back in before the rise? - I know you were hoping for 75p

just what we've been speaking of Darren - the pharma deal, the clinics, ovarian updates, oh, and the small matter of an FDA approval (remember folk will want to buy in before that happens..)

thanks Div - I missed the date on the US lab opening...

we should be getting some details on this next week - any thoughts on whether the US clinic will open first?

enjoyed the mixed botrytis metaphors Sain - Eden is the future of farming - but how long will it take to catch hold...?

it is a strong and confident update, with reports of additional, though not unexpected, efficacies. I just hope we get to Nasdaq whilst it remains in boom mode - it could easily double 4d MCAP overnight.

SoH means business

no censure of your English intended Shure! simply a reflection of Eden's provisional status...
something seems afoot these days however....

Definitely more interesting to speak of company matters Phantom, but I think it's ok to share strategies - it enables a balanced view IMO, but each to their own. GLA

a few pence not really worth worrying about - as it seems most of us are here for the big prize, north of £1.50 in a month (or so) and then onward to £4 and beyond....

feels like there will be a stampede in March - but only up to 50p - we will need Croda to drive it to that £1 mark.

I have no problem at all with traders wynd - I do a little myself (as with LOOP at the moment - as you suggest, I will be out with 10 - 20%, even though that can go much higher, and feed the profits back in here before the end of March). The thing with Angle is that its SP has been depressed by the Jupiter fiasco - had the last two RNSs arrived in 'normal' 'awaiting FDA' circumstances, I'd think it would be over £1 by now, with the big move still to come with FDA approval. Is your 10 - 20 % sufficient reward? What's hard to know (until the Pharma contract is announced) is whether the SP will dither whilst the FDA dither, or if expectation will keep driving it up. The mismatch been the enormous market opportunity and the puny MCAP is noteworthy, however.